0B68 Rui, Hallgeir - Thomas Jefferson University - Thomas Jefferson University
hxr001

Hallgeir Rui, MD, PhD

Contact Dr. Rui

Sidney Kimmel Cancer Center
233 South Tenth Street,
Suite 332
Philadelphia, PA 19107

(215) 503-9259
(215) 503-9246 fax

Most Recent Peer-reviewed Publications

  1. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression
  2. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  3. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury
  4. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer
  5. NADPH oxidase subunit p22phox-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer
  6. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment
  7. Global profiling of prolactin-modulated transcripts in breast cancer in vivo
  8. STAT5A/B gene locus undergoes amplification during human prostate cancer progression
  9. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer
  10. Dachshund binds p53 to block the growth of lung adenocarcinoma cells
  11. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer
  12. Population and target considerations for triple-negative breast cancer clinical trials
  13. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
  14. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
  15. Inflammatory signaling compromises cell responses to interferon alpha
  16. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression
  17. Reply to A. Italiano
  18. Differential expression of arrestins is a predictor of breast cancer progression and survival
  19. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma
  20. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure
0